![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Pfizer Wins Expanded Approval for Xalkori in Europe
Pfizer Wins Expanded Approval for Xalkori in Europe
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
The European Commission has approved an additional indication for Pfizer’s Xalkori for first-line treatment of adults with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer.
The summary of product characteristics also was updated to include additional efficacy data from the PROFILE 1014 global Phase 3 study, which demonstrated that Xalkori (crizotinib) prolonged progression-free survival in previously untreated patients with ALK-positive advanced nonsquamous NSCLC versus standard chemotherapy regimens.
The oral ALK inhibitor received accelerated approval by the FDA in 2011 for ALK-positive locally advanced or metastatic NSCLC.
Upcoming Events
-
21Oct